Programs/ Investments

Primary Indication

Prec

Phase 1

Phase 2

Phase 3

Psychedelic Programs & Strategic Investments

COMP3601 / Psilocybin

Treatment-Resistant Depression

Phase 3

Phase 3

BPL-0032 / 5-MEO-DMT

Treatment-Resistant Depression

Phase 2

Phase 2

DMX-1002 / Ibogaine

Opioid Use Disorder

Phase 1

Phase 1

VLS-01 / DMT

Treatment-Resistant Depression

Phase 1

Phase 1

ELE-1012 / Psilocin

Major Depressive Disorder

Phase 1

Phase 1

EMP-01 / R-MDMA

Post-Traumatic Stress Disorder & others

Phase 1

Phase 1

EGX-A & EGX-B / Novel 5-HT2A Receptor Agonists

Undisclosed

Preclin

Preclin

Non-Psychedelic Programs

RL-007 / Pro-cognitive neuromodulator3

Cognitive Impairment Associated with Schizophrenia

Phase 2

Phase 2

GRX-917 / Deuterated etifoxine

Generalized Anxiety Disorder

Phase 1

Phase 1

1 Strategic Investment in Compass Pathways
2 Strategic Investment in Beckley PsyTech
3 RL-007 compound is (2R, 3S)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one(L)-(+) tartrate salts

 

Strategic Investment

JOIN THE ATAI #INSIGHTNETWORK

Receive the latest news on atai and innovations in the space.

Email
submit